Clinical Trial

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 8, 2024 (before its estimated January 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with different tumor burden advanced-stage hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).
Trial Details
NCT Number NCT06632106
Lead Sponsor First Hospital of China Medical University
Conditions Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors, Hepatocellular Carcinoma (HCC)
Enrollment 97 participants
Start Date 2024-08-16
Primary Completion 2025-01-30 (estimated)
Study Completion 2025-05-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-08